开云app官网登录入口网页版-官方正版

#Regorafenib#

15篇内容 | 998人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1553751, encodeId=bde91553e517c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效, objectType=article, longId=723399, objectId=0052e23399a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0052e23399a4, replyNumber=0, likeNumber=108, createdTime=2022-04-05, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0052e23399a4, moduleTitle=Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0052e23399a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553750, encodeId=c8251553e5004, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性, objectType=article, longId=292745, objectId=425c292e45ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=425c292e45ea, replyNumber=0, likeNumber=80, createdTime=2021-12-26, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=425c292e45ea, moduleTitle=Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=425c292e45ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553749, encodeId=ccae1553e4956, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=65, createdTime=2021-11-28, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553748, encodeId=92081553e4890, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=J Clin Oncol：Avapritinib对比瑞戈非尼（Regorafenib）治疗局部进展不可切除或转移性胃肠道间质瘤的疗效：随机III期研究, objectType=article, longId=215316, objectId=4736215316ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4736215316ea, replyNumber=0, likeNumber=57, createdTime=2021-08-06, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4736215316ea, moduleTitle=J Clin Oncol：Avapritinib对比瑞戈非尼（Regorafenib）治疗局部进展不可切除或转移性胃肠道间质瘤的疗效：随机III期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4736215316ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553747, encodeId=8b8e1553e47e8, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=ANN ONCOL：Regorafenib治疗转移性结直肠癌患者的安全性和有效性, objectType=article, longId=154817, objectId=80ad15481e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80ad15481e9b, replyNumber=0, likeNumber=69, createdTime=2018-12-02, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80ad15481e9b, moduleTitle=ANN ONCOL：Regorafenib治疗转移性结直肠癌患者的安全性和有效性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=80ad15481e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553746, encodeId=48e91553e46a1, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=SCI REP：Regorafenib治疗胃肠道间质瘤的疗效, objectType=article, longId=111431, objectId=0791111431db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0791111431db, replyNumber=0, likeNumber=56, createdTime=2017-09-01, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0791111431db, moduleTitle=SCI REP：Regorafenib治疗胃肠道间质瘤的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0791111431db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553745, encodeId=34681553e4509, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=重磅！FDA今日批准近十年来肝癌药物regorafenib, objectType=article, longId=97456, objectId=552d9e45639, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=552d9e45639, replyNumber=0, likeNumber=56, createdTime=2017-04-30, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=552d9e45639, moduleTitle=重磅！FDA今日批准近十年来肝癌药物regorafenib, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=552d9e45639)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553744, encodeId=83491553e44f7, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=ESMO 2016：Regorafenib显著提高肝细胞癌患者生存期（附梅斯医学评论）, objectType=article, longId=71988, objectId=af3be19889a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af3be19889a, replyNumber=0, likeNumber=51, createdTime=2016-07-03, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af3be19889a, moduleTitle=ESMO 2016：Regorafenib显著提高肝细胞癌患者生存期（附梅斯医学评论）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=af3be19889a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553743, encodeId=4e9e1553e437c, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, objectType=article, longId=20869, objectId=d9a32086951, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9a32086951, replyNumber=0, likeNumber=68, createdTime=2013-07-05, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9a32086951, moduleTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d9a32086951)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553742, encodeId=ac101553e4296, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=ASCO2013：regorafenib治疗TKI抵抗性GIST效果不受KIT基因突变状态的影响, objectType=article, longId=19006, objectId=445d1900630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=445d1900630, replyNumber=0, likeNumber=71, createdTime=2013-05-22, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=445d1900630, moduleTitle=ASCO2013：regorafenib治疗TKI抵抗性GIST效果不受KIT基因突变状态的影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=445d1900630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553741, encodeId=a8a81553e41ea, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=ASCO2013：国立台湾大学Ann-Lii Cheng将开展Regorafenib治疗进展期肝细胞癌3期试验, objectType=article, longId=19004, objectId=56441900446, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56441900446, replyNumber=0, likeNumber=66, createdTime=2013-05-22, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56441900446, moduleTitle=ASCO2013：国立台湾大学Ann-Lii Cheng将开展Regorafenib治疗进展期肝细胞癌3期试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=56441900446)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553740, encodeId=e37f1553e40eb, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=FDA批准Regorafenib治疗转移性结直肠癌, objectType=article, longId=10344, objectId=52081034428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52081034428, replyNumber=0, likeNumber=63, createdTime=2012-10-13, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52081034428, moduleTitle=FDA批准Regorafenib治疗转移性结直肠癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=52081034428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553739, encodeId=a7941553e3995, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=拜耳和Onyx公布regorafenib胃肠道III期GRID研究积极数据, objectType=article, longId=6977, objectId=192969e72d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192969e72d, replyNumber=0, likeNumber=60, createdTime=2012-06-11, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192969e72d, moduleTitle=拜耳和Onyx公布regorafenib胃肠道III期GRID研究积极数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=192969e72d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553738, encodeId=44ff1553e3801, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=拜耳向EMA及FDA提交抗癌新药regorafenib上市许可申请, objectType=article, longId=6481, objectId=3b6464812c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b6464812c, replyNumber=0, likeNumber=58, createdTime=2012-05-26, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b6464812c, moduleTitle=拜耳向EMA及FDA提交抗癌新药regorafenib上市许可申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3b6464812c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1553737, encodeId=48f01553e3783, content=<a href='/topic/show?id=e96a15280ee' target=_blank style='color:#2F92EE;'>#Regorafenib#</a>, objectTitle=拜耳和Onyx公司公布regorafenib肠胃间质瘤III期研究积极数据, objectType=article, longId=5425, objectId=e98d5425fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e98d5425fc, replyNumber=0, likeNumber=59, createdTime=2012-04-18, rootId=0, userName=yilong5287547, userId=04aa14409774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e98d5425fc, moduleTitle=拜耳和Onyx公司公布regorafenib肠胃间质瘤III期研究积极数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e98d5425fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Regorafenib

2020-05-29

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

Front Oncol：国内多中心评估Regorafenib（瑞戈非尼）三线或以上治疗难治性转移性结直肠癌（mCRC）患者的疗效

2022-04-05

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性

2021-12-26

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2021-11-28

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

J Clin Oncol：Avapritinib对比瑞戈非尼（Regorafenib）治疗局部进展不可切除或转移性胃肠道间质瘤的疗效：随机III期研究

2021-08-06

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

ANN ONCOL：Regorafenib治疗转移性结直肠癌患者的安全性和有效性

2018-12-02

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

SCI REP：Regorafenib治疗胃肠道间质瘤的疗效

2017-09-01

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

重磅！FDA今日批准近十年来肝癌药物regorafenib

2017-04-30

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

ESMO 2016：Regorafenib显著提高肝细胞癌患者生存期（附梅斯医学评论）

2016-07-03

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗

2013-07-05

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

ASCO2013：regorafenib治疗TKI抵抗性GIST效果不受KIT基因突变状态的影响

2013-05-22

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

ASCO2013：国立台湾大学Ann-Lii Cheng将开展Regorafenib治疗进展期肝细胞癌3期试验

2013-05-22

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

FDA批准Regorafenib治疗转移性结直肠癌

2012-10-13

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

拜耳和Onyx公布regorafenib胃肠道III期GRID研究积极数据

2012-06-11

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

拜耳向EMA及FDA提交抗癌新药regorafenib上市许可申请

2012-05-26

yilong5287547 (审核中...)

前往app查看评论内容

#Regorafenib#

拜耳和Onyx公司公布regorafenib肠胃间质瘤III期研究积极数据

2012-04-18

科室
- - 订阅+
  - 更多科室
工具
服务